Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Asia-2020-Virtual-1000x250

The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

View the complete ESMO Asia Virtual Congress 2020 programme online

Saturday, 21 November 2020, 17:35-19:05 SGT

Channel 2

ESMO Colloquium: Breakthroughs in molecular profiling and systemic therapies of endometrial and ovarian cancer

ESMO-Asia-Virtual-Congress-Colloquia-GSK-Thumb

This educational activity is provided by ESMO and supported by GSK.

View the ESMO colloquium details

Learning Objectives
  • To provide an update on molecular profiles of actionable aberrations in gynaecologic malignancies 
  • To inform on the clinical research landscape of immunotherapy in advanced endometrial cancer 
  • To provide a comprehensive overview of the place of PARP inhibitors in the therapeutic armamentarium in advanced ovarian cancer and on available biomarkers 
  • To highlight ongoing research on optimal combination of immunotherapy with targeted agents in endometrial and ovarian cancer 

Channel 3

ESMO Colloquium: Optimising outcomes of patients with advanced prostate and urothelial cancer

ESMO-Asia-Virtual-Congress-Colloquia-Astellas-Thumb

This educational activity is provided by ESMO and supported by Astellas Pharma Singapore Pte. Ltd.

View the ESMO colloquium details

Learning Objectives
  • To provide a comprehensive overview of ADT combinations with androgen-targeting agents and chemotherapy in the therapeutic armamentarium in hormone-sensitive metastatic prostate cancer and discuss impact of first line combination regimens in the sequential therapeutic algorithm in advanced prostate cancer 
  • To provide a clear view of the therapeutic landscape in non-metastatic castration-resistant prostate cancer
  • To highlight emerging therapies in advanced urothelial cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings